Lycia Therapeutics, Inc. (NasdaqGS: LYCA)
Health Care · Biotechnology · US
$30.92
+8.07% today · +3.1% 1Y
Lycia Therapeutics, Inc. (NasdaqGS: LYCA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.78B and employs 65 people.
Over the last twelve months the share price has gained 3.1%, trading between 25.05 and 32.83.
Tweenvest scores Lycia Therapeutics, Inc. across four factors: quality 49/100, value 100/100. Its strongest factor is value.
LYCA price history
Key figures
- Market cap
- $1.78B
- Revenue (TTM)
- $4.44M
- P/E
- -59.39
- EPS
- -2.08
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $32.83
- 52-week low
- $25.05
- Avg volume (3M)
- —
- Shares outstanding
- 57.68M
- Employees
- 65
- Next earnings
- —
About Lycia Therapeutics, Inc.
Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.
- ISIN
- US55081P1003
- Founded
- 2019
- Listed since
- Oct 23, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Sino Biological,Inc.SZSE: 301047 | $1.81B | CN¥99.20 | -11.02% |
| Ultragenyx Pharmaceutical Inc.NasdaqGS: RARE | $1.80B | $17.73 | +6.23% |
| Zymeworks Inc.NasdaqGS: ZYME | $1.80B | $26.04 | +0.81% |
| Pell Bio-Med Technology Co., Ltd.TWSE: 6949 | $1.79B | NT$45.00 | +9.89% |
| Agios Pharmaceuticals, Inc.NasdaqGS: AGIO | $1.78B | $29.68 | -0.70% |
| Recursion Pharmaceuticals, Inc.NasdaqGS: RXRX | $1.76B | $2.83 | +3.86% |
| Stoke Therapeutics, Inc.NasdaqGS: STOK | $1.75B | $26.68 | +1.83% |
| Nurix Therapeutics, Inc.NasdaqGM: NRIX | $1.69B | $15.48 | -0.77% |